Wendy Li, M.D.Chief Medical Officer

Dr. Wendy Li rejoined EXUMA Biotech as Chief Medical Officer in June 2024. She brings over 20 years of experience in global clinical and medical strategy management, spanning early to late-stage development of MNC pharmaceutical companies in the U.S. and Asia. Dr. Li’s expertise spans clinical development and medical affairs, where she has led numerous global clinical trials targeting hematological malignancies, solid tumors, and autoimmune disorders. She has successfully overseen and led multiple global therapeutic Investigational New Drug (IND) applications, New Drug Applications (NDA), and Biologics License Applications (BLA).

Before rejoining EXUMA, Dr. Li served as CMO for Gracell Biotechnologies, providing deliberate medical and clinical leadership for the cell therapy pipeline and strategies in the U.S. and Asia. She has also held leadership roles in clinical development and medical affairs at Pfizer, Sanofi, Genentech, and Sihuan Pharmaceutical. Dr. Li earned her M.D. from Sun Yat-Sen University of Medical Sciences.